Compare Ascendis Pharma A/S (ASND) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Clear Secure Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Clear Secure Inc trades at $55.25 (market cap $5.56B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.09% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | YOU | |
|---|---|---|
Market Cap | $17.74B | $5.56B |
Sector | Health | Technology |
52-Week High | $277.18 | $62.36 |
52-Week Low | $163.32 | $28.38 |
Enterprise Value | $18.11B | $4.88B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Clear Secure (YOU) trades at $55.22, down 1.6% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Recent earnings beat expectations in Q1 2026, and the company expanded services with AWS integration and new airport launches. Revenue reached $900.78M in 2025, with net income of $109.17M and robust cash flow from operations of $372.45M.
Outlook remains positive due to earnings momentum and strategic expansions, but risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $56.67 price target, suggesting moderate upside potential from current levels amid balanced sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
